DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate.
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Category Reports Biotech
Tickers reports and analysis
Biotech Tape in Focus: $MBX Strengthens Phase 3 Setup, $JAZZ Hits Oncology Trial Risk, $KYMR Adds Platform Momentum
A fresh biotech tape with three very different clinical and regulatory signals: durable endocrine data from MBX Biosciences, a Phase 3 oncology setback for Jazz Pharmaceuticals, and a platform-supportive STAT6 degrader update from Kymera Therapeutics.
Cogent Biosciences (Nasdaq: $COGT) Deep Dive: Bezuclastinib, Three FDA Paths, and the EHA APEX Catalyst
A full Merlintrader research report on Cogent’s transition from late-stage precision-medicine developer to potential commercial biotech, with focus on bezuclastinib in systemic mastocytosis and GIST, the June 2026 EHA catalyst, dual 2026 PDUFA dates, management, ownership, balance sheet, dilution risk, and the bull/bear setup.
Disc Medicine (Nasdaq: $IRON): FDA Type A Meeting Keeps Bitopertin Alive After CRL
Disc Medicine has moved from regulatory disappointment to a defined late-2026 readout path. The FDA Type A meeting does not erase the Complete Response Letter, but it gives investors a clearer framework: APOLLO must deliver clinically and statistically, and if it does, bitopertin may still have a path toward a traditional approval decision around mid-2027.
RedHill Biopharma (Nasdaq: $RDHL): Opaganib Gets a Rare Pediatric Disease Designation, but the Bigger Story Is a High-Risk Pipeline Rebuild
RedHill Biopharma gained renewed attention after the FDA granted Rare Pediatric Disease designation to opaganib for neuroblastoma, adding a potential Priority Review Voucher angle. But the full RDHL story involves far more than a single designation. With limited cash, going-concern risk, Nasdaq compliance pressure, and a pipeline requiring external funding, this remains a high-risk, high-volatility catalyst watch demanding strict risk discipline.
Parabilis Medicines IPO Deep Dive: Helicon Peptides, Regeneron Validation, Zolucatetide Catalysts and the Real Risk Behind a Hot Biotech Debut: $PBLS
Parabilis Medicines enters Nasdaq after an upsized IPO with a rare mix of platform ambition, heavyweight private investors, Regeneron validation and a first-in-class oncology lead program. The opportunity is real, but so are the risks: early-stage clinical proof, no commercial revenue, post-IPO valuation pressure, and the challenge of turning a hard-to-drug biology platform into approved medicines.
$IDYA, $STTK, $ELOX: Biotech Funding Window Reopens, But Not All Dilution Looks the Same
Three biotech financing headlines crossed the market within the same short window: IDEAYA Biosciences (Nasdaq: $IDYA) priced a roughly $300 million public offering, Shattuck Labs (Nasdaq: $STTK) priced a roughly $75 million public offering, and Eloxx Pharmaceuticals (Nasdaq: $ELOX) announced a roughly $66 million public offering alongside an uplisting to the Nasdaq Capital Market.
Humacyte (Nasdaq: $HUMA): V012 Phase 3 Win Strengthens the Dialysis Access Story, While $50M Offering Defines the Near-Term Tape
V012 Phase 3 interim readout expected on June 11, 2026
Humacyte has said that top-line interim results from the Phase 3 V012 study in hemodialysis vascular access are expected to be available for reporting on June 11, 2026 at the SVS Vascular Annual Meeting in Boston. If the data are supportive, the company expects to pursue a supplemental BLA submission in the second half of 2026 for the AV access indication in hemodialysis patients.
Citius Oncology (Nasdaq: $CTOR): LYMPHIR Revenue Is Real Now, But the Commercial Launch Still Sits Inside a High-Risk Small-Cap Biotech Setup
Citius Oncology has moved beyond the old “approved asset waiting for launch” phase. LYMPHIR is now on the U.S. market, revenue has started, and payer/formulary access appears to be building. The same story, however, still carries serious small-cap biotech risks: dilution, limited runway, Nasdaq bid-price pressure, manufacturing transition, and extreme price volatility.
Nuvalent ($NUVL) Acquired by GSKfor $10.6 Billion
All-cash deal at $124 per share — 40% premium to prior close. GSK’s largest oncology acquisition in over a decade. Two NDAs under FDA review, one PDUFA in September 202
Oculis Holding AG (Nasdaq: $OCS): PREDICT-1 Starts as Licaminlimab Becomes the Next Test After the DIAMOND Phase 3 Miss
The first patient randomized in PREDICT-1 does not erase the DIAMOND disappointment, but it gives Oculis a fresh late-stage catalyst path. The equity story is now less about OCS-01 in DME and more about whether Licaminlimab and Privosegtor can rebuild confidence from a funded pipeline reset.
Tango Therapeutics (Nasdaq: $TNGX): 92% ORR Pancreatic Cancer Data and the $500M Offering
A full deep dive into the June 2026 vopimetostat + daraxonrasib readout, the PRMT5/RAS(ON) combination thesis, the role of Revolution Medicines, Tango's cash runway, pipeline optionality, ownership structure, key catalysts and the risks behind one of the strongest biotech moves of the year.
BioCardia ($BCDA) – CardiAMP Cell Therapy and the Road to FDA Premarket Approval
BCDA BioCardia deep dive — CardiAMP cell therapy, FDA PMA path confirmed June 2026, Japan PMDA Q4 2026. Educational content only.
Nurix Therapeutics (Nasdaq: $NRIX): Roche Deal Puts BTK Degradation Back in the Spotlight
A full trader-focused deep dive on Nurix Therapeutics, the Roche collaboration for bexobrutideg, the company’s targeted protein degradation platform, its clinical and partnered pipeline, financial runway, ownership profile, catalysts, risks and the scenarios that matter after the June 8 announcement.
Enliven Therapeutics (Nasdaq: $ELVN): ELVN-001 Faces the EHA 2026 Test
The June 11, 2026 catalyst is days away: oral presentation at EHA in Stockholm, updated Phase 1 data on ELVN-001 in chronic myeloid leukemia, and the pivotal Phase 3 ENABLE-2 trial launch expected in H2 2026. Cash of $452M, no near-term financing pressure, a new CEO with commercial ambitions.
Senseonics Holdings (Nasdaq: $SENS): ADA 2026 Real-World Data Puts the One-Year CGM Story Back in Focus
A deep-dive report on Senseonics after fresh ADA 2026 real-world evidence for Eversense 365, the first and only one-year implantable continuous glucose monitoring system, with new open-loop and closed-loop data, twiist AID integration, commercial momentum, European expansion, financing risk and the next execution test.
$ZBIO $VSTM $EDSA On the Move
Three biotechnology and healthcare names are standing out this morning for very different reasons. Zenas BioPharma (Nasdaq: $ZBIO) is the highest-quality fundamental setup among the group because the latest news is tied to a registrational Phase 3 dataset, a peer-reviewed medical publication, a major rheumatology conference and a recently submitted Biologics License Application. Verastem Oncology (Nasdaq: $VSTM) offers the cleanest oncology headline because the company has expanded the regulatory visibility of its KRAS G12D program through an FDA Fast Track designation in non-small cell lung cancer. Edesa Biotech (Nasdaq: $EDSA) is the most speculative of the three, but it has a timely conference catalyst in acute kidney injury, an area with high mortality, limited pharmacological options and a plausible inflammatory biology angle.
Oculis Holding AG (Nasdaq: $OCS): DIAMOND Phase 3 miss resets the story toward Privosegtor and Licaminlimab
After OCS-01 failed to meet the primary visual acuity endpoint in both DIAMOND Phase 3 trials for diabetic macular edema, Oculis is no longer a clean near-term DME filing story. The new setup is a cash-rich ophthalmology and neuro-ophthalmology pipeline reset, with Privosegtor and Licaminlimab now carrying the next real tests.
Primary endp
Fulcrum Therapeutics (Nasdaq: $FULC): Pociredir Discontinued, Strategic Review Begins After FDA Safety Concerns
Fulcrum was previously framed on Merlintrader as a cleaner but harsher one-asset biotech setup: pociredir had shown real fetal hemoglobin movement, but the next value bridge depended on FDA alignment, trial design and long-term safety confidence. The June 2026 update did not merely delay that bridge. It broke it.
Veru Inc. (Nasdaq: $VERU): Novo Nordisk Supply Agreement Puts Enobosarm Back on the Obesity Map
A single-stock deep dive on the Phase 2b PLATEAU trial, Wegovy supply, enobosarm’s GLP-1 adjunct thesis, FDA pathway, cash runway, dilution risk, catalysts, and the real bull-bear setup behind Veru.
June 2026 PDUFA Watchlist: Small and Mid-Cap Biotech Catalysts Beyond Big Pharma
A focused regulatory calendar screen for June, excluding major pharmaceutical companies and highlighting the smaller names where an FDA decision may still matter for valuation, narrative, liquidity, and trading behavior.